Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of cancer
3.2.1.2 Technological advancements in cancer biopsy techniques
3.2.1.3 Rising awareness in inherited oncology disorders and genetic testing
3.2.1.4 Expansion of research and development
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of biopsy devices
3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Technology landscape
3.5 Future market trends
3.6 Regulatory landscape
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Biopsy Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Tissue biopsy
5.2.1 Needle biopsy
5.2.2 Surgical biopsy
5.2.3 Other tissue biopsy types
5.3 Liquid biopsy
5.3.1 Circulating tumor cells (CTCs)
5.3.2 Circulating tumor DNA (ctDNA)
5.3.3 Other liquid biopsy types
5.4 Image-guided biopsy
5.5 Other biopsy types
Chapter 6 Market Estimates and Forecast, By Products & Services, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Products
6.2.1 Biopsy needles/ guns
6.2.1.1 Fine needle aspiration (FNA)
6.2.1.2 Core needle biopsy (CNB)
6.2.1.3 Vacuum-assisted biopsy devices
6.2.2 Biopsy forceps
6.2.2.1 General biopsy forceps
6.2.2.2 Hot biopsy forceps
6.2.3 Kits and reagents
6.2.4 Consumables
6.3 Services
Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Breast cancer
7.3 Colorectal cancer
7.4 Stomach cancer
7.5 Lung cancer
7.6 Liver cancer
7.7 Prostate cancer
7.8 Ovarian cancer
7.9 Other cancer types
Chapter 8 Market Estimates and Forecast, By End-user, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Cancer research centers
8.4 Diagnostic centers
8.5 Research and academics
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 ANGLE plc.
10.2 BD (Becton, Dickinson and Company)
10.3 Biodesix (Integrated Diagnostics)
10.4 Chronix Biomedical, Inc (Oncocyte Corporation )
10.5 Devicor Medical Products, Inc.
10.6 GRAIL, Inc.
10.7 Hologic, Inc.
10.8 Illumina, Inc.
10.9 IZI Medical Products
10.10 Lucence Health Inc.
10.11 Myriad Genetics, Inc.
10.12 Oncimmune Holdings PLC
10.13 Personal Genome Diagnostics Inc.
10.14 QIAGEN N.V.
